| SMITH, Denis |
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) | ITM Solucin GmbH | Neuroendocrine Tumors | 06/27 | 09/27 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
|
|
| Recruiting | 3 | 348 | Europe | Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 09/25 | 09/27 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Active, not recruiting | 2 | 99 | Europe | MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG | Anal Cancer | 02/23 | 12/24 | | |
| Completed | 2 | 77 | Europe | DONEPEZIL, PLACEBO | University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive | Digestive Oncology, Supportive Care | 01/24 | 01/24 | | |
| Active, not recruiting | 2 | 78 | Europe, US | Surufatinib, HMPL-012, sulfatinib | Hutchmed | Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET | 09/24 | 09/24 | | |
| Recruiting | 2 | 60 | Europe | Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab | Hospices Civils de Lyon, Roche, Inca | Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma | 10/23 | 10/23 | | |
| Active, not recruiting | 2 | 176 | Europe | Trifluridine/Tipiracil, Lonsurf | GERCOR - Multidisciplinary Oncology Cooperative Group | Metastatic Colorectal Cancer | 11/23 | 11/24 | | |
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI |
|
|
| Recruiting | 2 | 120 | Europe | Dostarlimab, Chemotherapy | UNICANCER, National Cancer Institute, France, GlaxoSmithKline | Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma | 10/28 | 09/30 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
| Active, not recruiting | 2 | 340 | Europe | Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib | UNICANCER, Bayer HealthCare Pharmaceuticals Inc. | Metastatic Colorectal Cancer | 11/24 | 05/28 | | |
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme |
|
|
| Recruiting | 2 | 400 | Europe | FOLFOX regimen, CAPOX regimen | UNICANCER | Digestive Cancer, Colorectal Cancer | 04/27 | 01/30 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
| Recruiting | 2 | 96 | Europe | Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Colorectal Cancer Metastatic, MSI-H Colorectal Cancer | 04/27 | 04/28 | | |
| Active, not recruiting | 2 | 140 | Europe | LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France | Pancreatic Cancer | 12/28 | 12/28 | | |
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas |
|
|
| Recruiting | 2 | 78 | Europe | Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment | GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD | Neuroendocrine Carcinoma, Digestive Cancer | 01/34 | 06/34 | | |
| Recruiting | N/A | 232 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Metastatic Colorectal Cancer, Circulating Tumor DNA | 09/25 | 06/27 | | |
